Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ran Frenkel Insider Profile
4 Followers
Ran Frenkel, EVP, Chief Dev. Officer at Karyopharm Therapeutics, holds 168.29K shares in Karyopharm Therapeutics (Ticker: KPTI).
Ran Frenkel Karyopharm Therapeutics (KPTI)EVP, Chief Dev. Officer
Karyopharm Therapeutics (KPTI)
EVP, Chief Dev. Officer
Ranked #21,495 out of 98,564 Corporate Insiders
Profitable Transactions
4 out of 7 Profitable Transactions
Average Return
+8.90%
Average return per transaction
Time Frame
Compare to
Insider Roles
EVP, Chief Dev. Officer
Roles that Ran Frenkel holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Sell
Date:Feb 22, 2022 - Feb 22, 2023
Return:+69.00%
The most profitable trade made by Ran Frenkel
Ran Frenkel's Trading History
List of latest transactions for each holding click on a transaction to see Ran Frenkel's performance on stock
You May Also Like
Ran Frenkel insider profile FAQ
What is the percentage of profitable transactions made by Ran Frenkel?
The percentage of profitable transactions made by Ran Frenkel is 57%.
What is the average return per transaction made by Ran Frenkel?
The average return per transaction made by Ran Frenkel is 8.90%.
What stocks does Ran Frenkel hold?
Ran Frenkel holds: KPTI stocks.
What was Ran Frenkel’s latest transaction?
Ran Frenkel latest transaction was an Uninformative Buy of ―.
What was Ran Frenkel's most profitable transaction?
Ran Frenkel’s most profitable transaction was an Informative Sell of KPTI stock on February 22, 2022. The return on the trade was 69.00%.
What is Ran Frenkel's role in Karyopharm Therapeutics?
Ran Frenkel's role in Karyopharm Therapeutics is EVP, Chief Dev. Officer.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.